Aug 11, 2020
Eisai Announces Topline Results from Study 211 Supporting 24 mg as the Appropriate Starting Dose for LENVIMA® (lenvatinib) in Patients with Differentiated Thyroid Cancer
May 13, 2020
COVID-19 Prompts New Home Test for Kids with Organ Transplants
Mar 19, 2020
Positive Results from Registrational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) in Advanced Endometrial Carcinoma Published in the Journal of Clinical Oncology
Feb 15, 2020
Eisai Announces Latest Data for LENVIMA® (lenvatinib) in Combination with Everolimus for Advanced Non-Clear Cell Renal Cell Carcinoma
Feb 10, 2020
Eisai to Present Latest on LENVIMA® (lenvatinib) at the 2020 Genitourinary Cancers Symposium
Jan 21, 2020
Eisai to Present Latest Data on LENVIMA® (lenvatinib) at the 2020 Gastrointestinal Cancers Symposium
Dec 10, 2019
Endo Launches Generic Version of Afinitor® (everolimus) Tablets in the United States
Sep 24, 2019
Eisai Announces Data Presentations on KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and HALAVEN® (eribulin) at ESMO 2019
Jul 23, 2019
SINOMED® Concludes Enrollment of the PIONEER III Randomized, Pivotal Study of the BuMA Supreme® Coronary Drug-Eluting Stent
Jun 27, 2019
CB-839 (Calithera Biosciences) Drug Overview 2019: CB-839 will be the First Glutaminase Inhibitor Approved for the Treatment of Renal Cell Carcinoma
May 16, 2019
Eisai Announces Data Presentations on Oncology Pipeline, including LENVIMA® (lenvatinib) plus KEYTRUDA® (pembrolizumab) Investigational Combination Therapy at ASCO 2019
Apr 10, 2019
Biodegradable Stents: Global Markets
Oct 09, 2018
Eisai to Present LENVIMA® (lenvatinib) and HALAVEN® (eribulin) Data in a Variety of Advanced Cancers at ESMO 2018 Congress
Sep 19, 2018
Health Canada Approves Ipsen's CABOMETYX(TM) (cabozantinib) Giving Physicians and Patients a Novel Second-Line Option in the Fight Against Advanced Renal Cell Carcinoma
Sep 17, 2018
Boston Scientific Announces Scheduled Presentations At Transcatheter Cardiovascular Therapeutics 2018
Aug 16, 2018
Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Jun 03, 2018
Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigational Studies of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy in Four Different Tumor Types
May 24, 2018
Eisai And Merck Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib in First-Line Unresectable Hepatocellular Carcinoma
May 23, 2018
Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR
May 23, 2018
Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease